Author

D. Awad

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:cancer & tumor microenvironment· 4 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:metabolism & bioenergetics· 2

Frequent Co-Authors

D. E. Frigo· 3 shared T. L. Pulliam· 3 shared C. A. Lyssiotis· 2 shared J. J. Ackroyd· 2 shared J. J. Han· 2 shared J. S. Oakhill· 2 shared J. W. Scott· 2 shared M. M. Ittmann· 2 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

D. E. Frigo

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Targeting PIKfyve-driven lipid homeostasis as a metabolic vulnerability in pancreatic cancer

C. Cheng, J. Hu, R. Mannan, R. Bhattacharyya, N. J. Rossiter, B. Magnuson, J. P. Wisniewski, Y. Zheng, L. Xiao, C. Li, D. Awad, T. He, Y. Bao, Y. Zhang, X. Cao, , A. M. Chinnaiyan

This study identifies PIKfyve as a targetable vulnerability in pancreatic cancer by showing its role in lipid metabolism and synthetic lethality with KRAS-MAPK inhibitors.

bioRxiv · Mar 18, 2024Cancer Biology

Type I interferon governs immunometabolic checkpoints that coordinate inflammation during Staphylococcal infection

M. B. Reynolds, B. Klein, M. J. McFadden, N. K. Judge, H. E. Navarrete, B. C. Michmerhuizen, D. Awad, T. L. Schultz, P. W. Harms, L. Zhang, T. R. O'Meara, J. Z. Sexton, C. A. Lyssiotis, J. M. Kahlenberg, M. X. O'Riordan

This paper shows type I interferon coordinates immunometabolic checkpoints during Staphylococcal infection by regulating metabolic and inflammatory programs in macrophages.

bioRxiv · Jan 10, 2024 · PreprintImmunology

SGC-CAMKK2-1: A chemical probe for CAMKK2

C. I. Wells, Y. Liang, T. L. Pulliam, C. Lin, D. Awad, B. Eduful, S. O Byrne, M. A. Hossain, C. Catta-Preta, P. Zonzini Ramos, O. Gileadi, C. Gileadi, R. M. Counago, B. Stork, C. G. Langendorf, , D. H. Drewry

This paper introduces SGC-CAMKK2-1, a selective chemical probe for CAMKK2, demonstrating its potential as a tool to study the therapeutic benefits of CAMKK2 inhibition.

Cells · Jan 11, 2023Peer-reviewedCancer Biology

Adipose triglyceride lipase is regulated by CAMKK2-AMPK signaling and drives advanced prostate cancer

D. Awad, T. L. Pulliam, M. L. Spradlin, P. H.-A. Cao, E. Subramani, T. V. Tellman, C. F. Ribeiro, H. Pakula, J. J. Ackroyd, M. M. Murray, J. J. Han, B. Piyarathna, J. M. Drake, M. M. Ittmann, C. Coarfa, , D. E. Frigo

This study identifies ATGL as a CAMKK2-AMPK target that promotes CRPC progression by enhancing lipase activity and metabolic plasticity, suggesting it as a therapeutic target.

bioRxiv · Nov 2, 2022 · PreprintCancer Biology

Systemic ablation of Camkk2 impairs metastatic colonization and improves insulin sensitivity in TRAMP mice: Evidence for cancer cell-extrinsic CAMKK2 functions in prostate cancer

T. L. Pulliam, D. Awad, J. J. Han, M. M. Murray, J. J. Ackroyd, P. Goli, J. S. Oakhill, J. W. Scott, M. M. Ittmann, D. E. Frigo

This study shows that deleting Camkk2 in TRAMP mice reduces metastasis and improves insulin sensitivity, suggesting CAMKK2 has non-autonomous roles in prostate cancer progression.

bioRxiv · Mar 28, 2022Cancer Biology